UK Markets open in 7 hrs 11 mins

Senseonics Holdings, Inc. (SENS)

NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
2.3200-0.2800 (-10.77%)
At close: 04:00PM EST
2.3600 +0.04 (+1.72%)
After hours: 07:41PM EST
Full screen
Trade prices are not sourced from all markets
Previous close2.6000
Open2.3100
Bid2.3400 x 21500
Ask2.3500 x 2900
Day's range2.2701 - 2.4300
52-week range1.6200 - 5.5600
Volume7,566,234
Avg. volume9,462,937
Market cap1.035B
Beta (5Y monthly)0.50
PE ratio (TTM)N/A
EPS (TTM)-1.3090
Earnings date02 Mar 2022 - 07 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est3.58
  • Business Wire

    Senseonics Announces Equity Grants To Employees Under Inducement Plan

    GERMANTOWN, Md., January 05, 2022--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the "Plan") in accordance with NYSE American Company Guide Section 711(a).

  • Business Wire

    Senseonics Announces Business Updates

    GERMANTOWN, Md., January 04, 2022--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced operational and financial business updates.

  • Business Wire

    Eversense NOW Remote Monitoring App for Android Users Receives CE Mark in Europe

    GERMANTOWN, Md., December 21, 2021--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it received CE mark of the Eversense® NOW Remote Monitoring App for the Android Operating System. The Eversense NOW iOS platform has previously been approved and is currently available in Europe.